CACNB2: A Voltage-Dependent L-Type Calcium Channel Subunit Beta-2 (ISO Form 9) as a Drug Target and Biomarker

Target Name: CACNB2

NCBI ID: G783

CACNB2

Other Name(s): Voltage-dependent L-type calcium channel subunit beta-2 (isoform 9) | Voltage-dependent L-type calcium channel subunit beta-2 (isoform 1) | FLJ23743 | calcium channel voltage-dependent subunit beta 2 | CACNB2 variant 6 | lambert-Eaton myasthenic syndrome antigen B | CACNB2 variant 8 | calcium voltage-gated channel auxiliary subunit beta 2 | CACNB2 variant 1 | Calcium voltage-gated channel auxiliary subunit beta 2, transcript variant 5 | Calcium channel voltage-dependent subunit beta 2 | Calcium voltage-gated channel auxiliary subunit beta 2, transcript variant 1 | myasthenic (Lambert-Eaton) syndrome antigen B | Voltage-dependent L-type calcium channel subunit beta-2 (isoform 2) | MYSB | CAVB2 | calcium channel, voltage-dependent, beta 2 subunit | CACNB2 variant 2 | CACNB2 variant 5 | CACNLB2 | CACNB2 variant 4 | Voltage-dependent L-type calcium channel subunit beta-2 (isoform 6) | Voltage-dependent L-type calcium channel subunit beta-2 (isoform 5) | CACNB2 variant 9 | Lambert-Eaton myasthenic syndrome antigen B | Voltage-dependent L-type calcium channel subunit beta-2 (isoform 4) | Calcium voltage-gated channel auxiliary subunit beta 2, transcript variant 8 | Calcium channel, voltage-dependent, beta 2 subunit | CACNB2c | CAB2 | Calcium voltage-gated channel auxiliary subunit beta 2, transcript variant 6 | Voltage-dependent L-type calcium channel subunit beta-2 (isoform 8) | Myasthenic (Lambert-Eaton) syndrome antigen B | Calcium voltage-gated channel auxiliary subunit beta 2, transcript variant 4 | Voltage-dependent L-type calcium channel subunit beta-2 | Calcium channel, voltage-dependent, beta 2 subunit, transcript variant 9 | Calcium voltage-gated channel auxiliary subunit beta 2, transcript variant 2 | CACB2_HUMAN | CACNB2d

CACNB2: A Voltage-Dependent L-Type Calcium Channel Subunit Beta-2 (ISO Form 9) as a Drug Target and Biomarker

Abstract:

CACNB2, or voltage-dependent L-type calcium channel subunit beta-2, is a protein that plays a crucial role in the regulation of calcium ions in various physiological processes. The CACNB2 gene has been identified as a potential drug target and biomarker for various neurological and psychiatric disorders. This article will summarize the current research on CACNB2, including its function, potential drug targets, and potential as a biomarker.

Introduction:

Ca2+ is a vital signaling molecule that plays a crucial role in various physiological processes, including muscle contractions, nerve function, and brain function. However, abnormal Ca2+ levels can lead to the development of neurological and psychiatric disorders, such as Alzheimer's disease, Parkinson's disease, and epilepsy. The CACNB2 gene has been identified as a potential drug target and biomarker for these disorders due to its unique function in the regulation of calcium ions.

Function of CACNB2:

CACNB2 is a voltage-dependent L-type calcium channel subunit that is expressed in various tissues, including brain, heart, and muscle. It plays a crucial role in the regulation of calcium ions in these tissues, allowing it to maintain the proper levels of calcium ions to support various physiological processes.

CACNB2 is composed of two subunits, alpha and beta, which are held together by a disulfide bond. The alpha subunit consists of an N-terminus, a catalytic alpha-helices region, and a C-terminus. The beta subunit is similar to the alpha subunit but has a different C-terminus.

Potential Drug Targets:

CACNB2 has been identified as a potential drug target due to its role in the regulation of calcium ions. Several studies have shown that inhibiting CACNB2 can lead to the relaxation of muscle contractions, an effect that is typically observed in individuals with Alzheimer's disease. Additionally, CACNB2 has been shown to play a role in the regulation of neurotransmitter release, which is a crucial aspect of brain function.

Potential Biomarkers:

CACNB2 has also been identified as a potential biomarker for various neurological and psychiatric disorders. Studies have shown that individuals with Alzheimer's disease have lower levels of CACNB2 compared to healthy individuals. Additionally, individuals with major depressive disorder have lower levels of CACNB2 compared to healthy individuals..

Conclusion:

CACNB2 is a voltage-dependent L-type calcium channel subunit that plays a crucial role in the regulation of calcium ions in various physiological processes. Its unique function as a protein that is expressed in various tissues makes it an attractive drug target and biomarker for various neurological and psychiatric disorders. Further research is needed to fully understand the role of CACNB2 in the regulation of calcium ions and its potential as a drug target and biomarker.

Protein Name: Calcium Voltage-gated Channel Auxiliary Subunit Beta 2

Functions: Beta subunit of voltage-dependent calcium channels which contributes to the function of the calcium channel by increasing peak calcium current (By similarity). Plays a role in shifting voltage dependencies of activation and inactivation of the channel (By similarity). May modulate G protein inhibition (By similarity). May contribute to beta-adrenergic augmentation of Ca(2+) influx in cardiomyocytes, thereby regulating increases in heart rate and contractile force (PubMed:36424916). Involved in membrane targeting of the alpha-1 subunit CACNA1C (PubMed:17525370)

The "CACNB2 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about CACNB2 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets